ClinicalTrials.gg
Not yet recruitingNCT06861894Updated May 15, 2025

Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC

A Phase 2 interventional study of Adebrelimab and nab-paclitaxel and carboplatin and Radiation in Esophageal Squamous Cell Carcinoma, sponsored by Zhigang Li. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-15.

Sponsored by Zhigang Li · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
164
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies testing adebrelimab in Esophageal Squamous Cell Carcinoma — 12 open to participants now, 14 under way, none of them phase 3. adebrelimab · Esophageal Squamous Cell Carcinoma.

Planned enrollment
Largest of 15
164 · median 42
Started
2025
with 1 other
Phase 2
14 of 15
12 open now
Primary completion
2027-03
later than 7 of 13 live
Registered
10th of 15
by date

Among the 15 studies testing adebrelimab in Esophageal Squamous Cell Carcinoma, this one has the largest planned enrollment, is one of 2 that started in 2025, is one of 14 in phase 2, reaches primary completion later than 7 of the 13 other live ones, and was the 10th registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

12 of the 15 studies testing adebrelimab in Esophageal Squamous Cell Carcinoma are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

About adebrelimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing adebrelimab in Esophageal Squamous Cell Carcinoma, or all of them as a file.
02

Study summary

In this prospective trial, patients demonstrating clinical complete response (cCR) as determined by a standard response assessment protocol (incorporating clinical and molecular diagnostic methods) will be offered organ-sparing management following neoadjuvant therapy with adebrelimab (anti-PD-L1) concurrent with chemoradiotherapy. The primary endpoint is 2-year overall survival rate in this watch-and-wait cohort.

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects signed the and volunteered to participate in the study.
  2. Esophageal squamous cell carcinoma confirmed by histology or cytology.
  3. Thoracic esophageal squamous cell carcinoma confirmed by CT or pet-CT, which is classified as cII-III (AJCC 8th).
  4. Expect to have R0 resection
  5. In age from 18 to 75.
  6. PS: 0\~1.
  7. Have not received any anti-tumor treatment for esophageal cancer in the past, including radiotherapy, chemotherapy, surgery, etc.
  8. No to surgery.
  9. Has sufficient organ function including (1) Blood routine: NE≥1.5×109/L; ≥100×109/L; HGB≥90 g/L (2)Comprehensive Metabolic Panel: ≤ 1.5×; ≤2.5×ULN; AST≤2.5×ULN; sCr≤1.5×ULN or ≥50 mL/min(Cocheroft-Gault) (3) Coagulation function: ≤1.5; APTT≤1.5×ULN
  10. Women of childbearing age must undergo a serological pregnancy test within 72 hrs before first administration. Women of childbearing age, or male subjects with childbearing age female partners, must take measures from the first dose to three months after last administration.
  11. Good compliance, willing to comply with follow-up schedules.

Exclusion criteria

Exclusion Criteria:

  1. Subjects have received or are receiving any of:

    1. anti-tumor interventions such as radiotherapy, chemotherapy, or other medications.
    2. or systemic glucosteroids (prednisone equivalence> 10mg/d) within 2 weeks before the first administration, inhaled or topical use of glucosteroids (prednisone equivalence>10mg/d) is allowed if no known active disease.
    3. within 4 weeks before the first administration.
    4. major surgery or major injury within 4 weeks before the first administration.
  2. Cancer-related exclusion criteria

    1. other cancers instead of ESCC
    2. unresectable or ESCC
    3. not comply with cⅡ-Ⅲ(cT2N1-2M0 or cT3N0-2M0, AJCC 8th)
    4. Subjects with other malignant tumors within 5 years before the first administration, but subjects with cervical carcinoma in situ, skin basal cell carcinoma, skin squamous cell carcinoma, localized prostate cancer received radical surgery and ductal carcinoma in situ that have received radical treatment and do not need other treatment can be included)
  3. Other criteria

    1. Subjects have uncontrolled cardiovascular diseases, such as 1) heart failure ≥ class 2, 2) unstable angina 3) myocardial infarction within 1 year; 4) supraventricular or ventricular arrhythmia that needs treatment
    2. Subjects with any known active autoimmune disease
    3. Pregnant or breastfeeding female
    4. Presence of allergy or to medications
    5. -positive or active (HBsAg positive and HBV-DNA ≥2000 IU/ml or ≥ 104 copies/mL) or active (HCV antibody positive) or active tuberculosis
    6. Investigators assessed there might be other factors that cause subjects to withdraw.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
164 participants (estimated)

Study arms

  • Experimental
    perioperative treatment with adebrelimab and CRT

    Drug: Adebrelimab and nab-paclitaxel and carboplatin · Radiation: Radiation · Procedure: standard oesophagectomy · Other: active surveillance

Interventions

06

What researchers measure

Primary outcomes

  1. 2-year OS rate

    An overall survival (OS) is defined as the time from treatment to death, regardless of disease recurrence.

    Time frame: 24 months

Secondary outcomes

  1. cCR rate

    A clinical complete response rate (cCR) is defined as the complete disappearance of tumor lesions.

    Time frame: 12 months

  2. median EFS

    An event-free survival (EFS) is defined as the duration from the start of treatment until disease recurrence or death from any cause, whichever occurs first.

    Time frame: 24 months

  3. median OS

    An overall survival (OS) is defined as the time from treatment to death, regardless of disease recurrence.

    Time frame: 24 months

  4. Incidence, type and severity of adverse events as assessed by CTCAE 5.0

    Including adverse events and complications. Incidence of adverse events using CTCAE 5.0; grade 3 adverse events and higher-grade will be reported.

    Time frame: 24 months

  5. quality of life (QOL)

    Evaluate quality of life using EORTC QLQ-C30

    Time frame: 24 months

  6. quality of life (QOL) assessed by EORTC QLQ-OES18

    Evaluate quality of life using EORTC QLQ-OES18

    Time frame: 24 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Mar 2027, 20 months later.

Of 153 non-industry phase 2 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 55. This study's planned 20 months is below that.

Counting every sponsor, half of 174 studies reached it within 41 months; a quarter within 28 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2025
First posted
Mar 6, 2025
StartEst.
Jul 2025
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2029
Last update
May 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06861894
Lead sponsor
Zhigang Li
Responsible party
Zhigang Li (Chief of Department of Esophageal Surgery, Shanghai Chest Hospital) — Sponsor-investigator
First posted
Mar 6, 2025
Start date
Jul 2025 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Mar 2029 (estimated)
Last update
May 15, 2025

Study contacts

Zhigang Li, MD, PhD
Contact
zhigang.li@shsmu.edu.com
86-18960619260
Zhichao Liu, MD, PhD
Contact
zhichao.liu@sjtu.edu.cn
86-15622175948

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adebrelimab · Albumin-Bound Paclitaxel · Carboplatin

Start the discussion